How Compounding Pharmacies Fill Critical Gaps in Pediatric Drug Development Processes: Suggested Regulatory Changes...

Area of Science:

• Pediatric pharmacology
• Drug regulation
• Pharmaceutical development

Background:

• Most drugs used in children are administered off-label, requiring specialized preparation.
• Compounded preparations include those from US-FDA approved forms or bulk active pharmaceutical ingredients (APIs).
• Compounding occurs in 503A pharmacies for individual patients or 503B establishments for larger scales.

Purpose of the Study:

• To describe current US-FDA regulatory processes for pediatric drug approval.
• To identify gaps in regulatory pathways for manufactured and compounded pediatric drugs.
• To suggest modifications for enhanced pediatric product development.

Main Methods:

• Review of current US-FDA regulatory processes for pediatric drug approval.
• Analysis of regulatory pathways for finished dosage forms and compounded preparations.
• Identification of challenges impacting pediatric drug development and availability.

Main Results:

• The current pediatric drug approval process presents significant challenges, creating a 'Gordian knot'.
• Gaps exist in regulatory pathways for both manufactured and compounded pediatric drugs.
• These gaps complicate and delay the development and patient availability of pediatric medications.

Conclusions:

• Reforming regulatory processes is crucial to increase the production and approval of pediatric drugs.
• Addressing identified gaps can enhance pediatric product development strategies for manufacturers and compounders.
• Thoughtful untangling of regulatory complexities is needed to improve access to vital medications for children.